Kornimate/medical-research-clean huggingface dataset:
[18f]fmiso pet/ct after transcatheter arterial embolization in imaging tumors in patients with liver cancer

Conditions: Adult Liver Carcinoma; Liver Cirrhosis

Summary: this clinical trial studies how well 18f-fluoromisonidazole (\[18f\]fmiso) positron emission tomography (pet)/computed tomography (ct) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. \[18f\]fmiso is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by \[18f\]fmiso is picked up by a pet scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible

primary objectives: i. determine the variability of 18f fmiso uptake in hepatocellular carcinoma (hcc) tumors compared to normal liver after transcatheter arterial embolization by determining the difference in the mean of the maximum standardized uptake value (suvmax) and tumor-to-liver ratio (tlr) of a region of normal liver and of up to 5 index tumors. secondary objectives: i. determine if areas of tumor recurrence as determined by ct or magnetic resonance imaging (mri) within a 6 month period after transcatheter arterial embolization show evidence of increased 18f fmiso labeling on the initial post treatment 18f fmiso pet/ct. ii. determine the variability in suvmax and tlr of untreated (non embolized) hcc lesions compared to normal liver by determining the difference in the mean of the suvmax and tlr of normal liver and tumor. iii. determine any toxicities related to \[18f\]fmiso use for pet/ct. outline: patients undergo transcatheter arterial embolization. patients also receive 18f-fluoromisonidazole intravenously (iv) and undergo pet/ct scans within 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment. after completion of treatment, patients are followed up at 2 and 3 months.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * histopathologic or imaging and clinical features of tumor(s) diagnostic for hepatocellular carcinoma with at least one tumor \>= 1.5 cm; imaging features diagnostic for hepatocellular carcinoma will be defined as liver imaging reporting and data system (lirads) 4 or greater * total bilirubin \< 3.0 * child pugh a or b * tumor amenable to transcatheter arterial embolization * able to provide informed consent exclusion criteria: * uncontrolled large ascites * main or segmental portal vein thrombosis * locoregional treatment of hepatocellular carcinoma within the prior 3 months or chemotherapy within the previous 3 months * inability or contraindication to undergo transcatheter arterial embolization * inability to lay flat for at least 2 consecutive hours * severe acute illness * uncontrolled chronic illness such as hypertension, diabetes, or heart failure * contraindication to ct or mri contrast * pregnancy
outcomes of isolated lcx occlusion

Conditions: LCx Occlusion STEMI; STEMI

Summary: to assess procedural success and short term clinical outcomes of primary pci to isolated lcx acute occlusion.

st-segment elevation myocardial infarction (stemi) involving acute occlusion of the left circumflex (lcx) coronary artery represent only 14-21% of stemis lcx acute occlusion may be difficult to be diagnosed . only 50% of patients with lcx occlusion exhibited st segment elevation during the acute phase, 38% showed no st segment changes, while 15% presented with isolated st segment depression this may lead to delay in transfer to cath lab, delay in reperfusion therapy and consequently loss of more myocytes and more major adverse cardiovascular events (mace) . due to relative rare occurrence of isolated lcx coronary artery occlusion, little is known in literature about the clinical outcomes of isolated lcx occlusion , so we will conduct a retrospective observational study in our tertiary primary percutaneous coronary intervention (pci) center to detect the incidence , procedural and clinical outcomes after 6 months of patients who had isolated lcx acute occlusion and underwent primary pci.

Eligibility criteria:
inclusion criteria: * patients presented to assiut university heart hospital with stemi who underwent primary pci that revealed isolated lcx acute occlusion (single culprit artery) between january 2018 to january 2025 will be included. exclusion criteria: -patients with cardiogenic shock, nyha class iii-iv and multivessel coronary artery disease will be excluded.

Keywords: lcx occlusion stemi
pacific northwest female urinary incontinence treatment digital awareness project

Conditions: Urinary Incontinence

Summary: the investigators will compare whether advertisements on google or facebook are more effective to reach women in the pacific northwest about treatment options for urinary incontinence through the american urogynecologic society's patient education website, voicesforpfd.org. the investigators hypothesize there is no difference in the overall population engagement between these two platforms due to anticipated higher reach through facebook based on user characteristics but higher engagement through google due to higher user interest on this platform.

the investigators will conduct a comparative ecological study to compare effectiveness of two different targeted digital outreach platforms to engage women at risk for urinary incontinence in the pacific northwest. counties in oregon, washington, idaho will be randomized to receive advertisements for the american urogynecologic society's patient education website (domain voicesforpfd.org) via either google or facebook. the investigators will use advertising campaigns developed specifically for this purpose. through website analytics measuring advertisement clicks and census population data, the investigators will estimate utilization rates of the website for each county among the target population of middle-aged women to determine if one platform is more effective than the other for this topic and population.

Eligibility criteria:
inclusion criteria: - internet user in idaho, oregon, or washington states exclusion criteria: * identified geographic location outside idaho, oregon, or washington states * users identified by the advertising platforms as male.

Keywords: female advertising urinary incontinence social media search engine internet quality of life feasibility studies
guided internet-based interventions in primary care effectiveness-implementation randomized controlled trial

Conditions: Anxiety; Mild to Moderate Depression

Summary: internet-based cognitive behavioral therapy for anxiety and depression have far-reaching potential to overcome common barriers to accessing evidence-based treatment, such as waiting lists, travel distance and costs. despite the undeniable promise of icbt, several aspects remain poorly understood and warrants further study. the intermental project is a joint effort between norwegian institute of public health, norwegian directorate of health and six prompt mental health care (pmhc) services, situated in 11 municipalities, to evaluate the icbt interventions developed by the technology company "assistert selvhjelp" (as-icbt). we will conduct a large-scale hybrid effectiveness-implementation randomized controlled non-inferiority trial that will provide new knowledge on the effectiveness, cost-effectiveness and implementation of as-icbt in primary care. primary objective: examine the non-inferiority of guided internet-based cognitive behavioural treatment "assistert selvhjelp" (as-icbt) compared to treatment as usual in the primary care service prompt mental health care (tau-pmhc) with regard to effects on symptoms of anxiety and depression. secondary objectives: (i) examine the non-inferiority of as-icbt compared to tau-pmhc on other outcomes such as quality of life, functional level, specific anxiety measures (social anxiety, panic disorder), sleep and employment status; (ii) examine the cost-effectiveness of as-icbt compared to tau-pmhc; (iii) examine to what extent moderators and mediators of change are associated with treatment effectiveness of as-icbt; (iv) assess whether as-icbt is as acceptable and appropriate for treatment of anxiety and depression as tau-pmhc, and examine barriers/facilitators for their further implementation.


Eligibility criteria:
inclusion criteria: * presence of anxiety and/or mild to moderate depression. * being above 18 years of age and a resident in the pilot sites. * basic verbal and oral norwegian proficiency. * having internet access and ability to use it. exclusion criteria: * entitled to secondary care services due to eating disorder, suicide risk, bipolar disorder, severe depression, psychotic symptoms, severe substance abuse, and/or personality disorder. * two or more previous treatment attempts in secondary care services without effect. * serious physical health problem as primary problem. * clients that have had treatment at pmhc before and only require a booster session.

Keywords: anxiety depression guided internet-based interventions cbt outcome monitoring dissemination routine services
enhancing operability in a hypobaric hypoxic environment with a small oxygen storage system

Conditions: Hypobaric Hypoxemia

Summary: this is a study to validate the efficacy of using a small portable oxygen source to mitigate altitude-induced hypoxia.

the purpose of this study is to validate the efficacy of using a small portable oxygen source to mitigate altitude-induced hypoxic events. to do so, the invesitgators propose the following aims: 1. determine the ability of a portable oxygen storage device to reverse hypobaric hypoxemia in volunteers at altitude. 2. determine the duration of time that a single portable oxygen container can maintain normoxia in normal volunteers at altitude. 3. determine the optimum dose and timing of oxygen use to reverse hypobaric hypoxemia.

Eligibility criteria:
inclusion criteria: * altitude chamber qualified * previous agreement to be approached regarding altitude chamber research exclusion criteria: -
the number and function of regular t cell in patients with obstructive sleep apnea

Conditions: Sleep Apnea Syndromes

Summary: to compare the number and function of regular t cell of patients with obstructive sleep apnea (osa) versus that of age-, gender- and bmi (body mass index)-matched controls

patients with obstructive sleep apnea (osa) experience intermittent hypoxemia and arousal during sleep due to recurrent collapse of upper airway. epidemiologic evidence showed they were at higher risk for autoimmune diseases. the regular t cell (treg) has a crucial role in controlling autoimmunity. in this study, 40 osa patients and 40 age-, gender- and bmi-matched controls will be recruited. peripheral venous blood of the participants is drawn for numeration of cd4+cd25+foxp3+ regular t cells by flow cytometry. as well, the cd4+cd25+ regular t cells are enriched by macs and tested for their suppressive functions on proliferation assays. th12+ cd4+ cells are also measured.

Eligibility criteria:
inclusion criteria: 1. osa patients diagnosed with a polysomnography 2. agree to participate the study and sign informed consent exclusion criteria: 1. do not agree to participate the study and sign informed consent 2. has received any treatment or osa 3. with major comorbidities (such as a diabetes, heart disease, lung diseases, renal diseases, autoimmune diseases, but hypertension excluded) 4. history of sarcoidosis and tuberculosis 5. on treatment of steroid and immunosuppressant

Keywords: sleep apnea intermittent hypoxia regulatory t cell autoimmunity
gas transfer on ila-activve

Conditions: Hypercapnia

Summary: oxygenatuion and decarboxylation during different settings (steps of blood flow and sweep gas flow) of extracorporeal gas exchange by ila activve using a jugular 22french double lumen cannula are measured.


Eligibility criteria:
inclusion criteria: * patient on ila activve * controlled mechanical ventilation * no spontaneous breathing exclusion criteria: - pregnancy
to study the effect of β-glucans on wound healing

Conditions: Burns

Summary: the purpose of this study is to determine the effect of β-glucans on wound healing.

the structure of βeta-glucan (β-glucans) is a pathogen associated molecular patterns (pathogen-associated molecular patterns, pamps), widely present in the cell walls of plants, bacteria, yeasts, fungi, mushrooms and algae. modern has been reported in the literature that β-glucan can enhance the immune system of animals, and to enhance the function of the animal against bacterial, fungal and viral infections, and cancer.in this study, the use of β-glucan to enhance the biological characteristics of the non-specific immunity, to explore the impact of postoperative patients with wound healing and infection rates.the observation of the healing process to take the leather district wounds (5 \~ 200 cm2). the experiments were carried out for 18 months, were observed record the following three: (1) the rate of wound healing, (2) the rate of infection assessment: record length of time and the point in time at all levels of antibiotic use also observe the wound change (redness, swelling, heat, pain).(3) days of hospitalization, and spend statistics. using unpaired student's t-test analysis, group data whether the differences between groups of experimental data. represents a statistically significant when p \<0.05.

Eligibility criteria:
inclusion criteria: 1. total burn area under 20%, two to three degree burn and need skin-grafting. 2. subjects don't have other diseases. 3. subjects' age between 20 to 60. exclusion criteria: 1. subjects with hypersensitivity. 2. subjects with autoimmune disease.

Keywords: burn, wound healing, skin graft
protecting with arni against cardiac consequences of coronavirus disease 2019

Conditions: Covid19

Summary: the purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute covid-19 infection.


Eligibility criteria:
inclusion criteria: 1. patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test 2. systolic blood pressure ≥100 mmhg at screening 3. ≥18 years of age 4. successful collection of baseline serum biomarkers 5. successful completion of baseline eq-5d questionnaire 6. successful completion of baseline cmr study (cmr sub-study only) 7. high-sensitivity troponin t at or above the level of detection on screening labs 8. presence of ≥1 of the following: 1. age ≥60 2. history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. diabetes mellitus (type 1 or type 2) 4. body mass index ≥35 kg/m2 5. egfr 30-60 ml/min/1.73m2 6. history of atrial fibrillation/flutter exclusion criteria: 1. fever within the past 96 hours of \>100.3 degrees fahrenheit 2. actively receiving therapy with an angiotensin-converting enzyme inhibitor (acei), angiotensin ii receptor blocker (arb), aliskiren, or sacubitril/valsartan 3. last known left ventricular ejection fraction of ≤40% 4. egfr \<30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. serum potassium \>5.0 meq/l on screening labs 6. prior intolerance, allergy or angioedema to acei, arb, or sacubitril/valsartan 7. pregnant or breast-feeding 8. in women of childbearing age, unwillingness to use birth control for the duration of the study 9. history of heart transplant or durable left ventricular assist device 10. currently implanted permanent pacemaker, defibrillator, or other device that would preclude cmr testing (cmr sub-study only) 11. currently participating in another trial of an investigational medication or device for covid-19. 12. any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

Keywords: sacubitril/valsartan
an observational study on safinamide, rasagiline and other standard of care in pd

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate how safinamide, rasagiline and other soc drugs are associated with the quality of life of pd patients by means of the parkinson's disease questionnaire (pdq)-39 items.

safinamide is an alpha-aminoamide derivative, structurally unrelated to any other drug for the treatment of pd, with a dual mechanism of action (dopaminergic and non-dopaminergic). in particular, it is a potent, selective and reversible mao-b inhibitor, and it is a glutamate modulator through the sodium channels blockade. safinamide has been approved in europe for the treatment of mid- to late-stage patients with idiopathic pd and fluctuations as add-on therapy to a stable dose of levodopa (alone or in combination with other pd medications). rasagiline is an irreversible mao-b inhibitor, with unknown activity on other neurotransmitters. rasagiline has been approved in europe for the treatment of idiopathic pd as monotherapy or as add-on to levodopa in patients with end of dose fluctuations. the aim of this observational study is to evaluate the effectiveness of safinamide, rasagiline and other "standard of care" (soc) drugs when prescribed in clinical routine as add-on to l-dopa in terms of quality of life, improvement of chronic pain, change in anti-parkinson treatment (modification of doses, addition or withdrawal or other anti-parkinson drugs, etc.), use of concomitant pain-killer medications, compliance to the pd treatment, hospitalizations and use of other healthcare resources, and number of lost working days.

Eligibility criteria:
inclusion criteria: * patients of both genders ≥ 18 years of age, with a clinical diagnosis of idiopathic pd according to uk brain bank diagnostic criteria (12) for whom safinamide, rasagiline or any other anti-parkinson drugs are prescribed according to the current summary of product characteristics (smpc). * willing to participate in the study and able to understand and sign the written informed consent form. * patients on a stable anti-parkinson therapy, always including l-dopa + dopa-decarboxylase inhibitor (ddi), with or without other anti-parkinson medications. * patients must be treated with safinamide, rasagiline or other soc drugs as add-on to l-dopa for no more than 2 months prior to the baseline visit, according to the clinical practice. exclusion criteria: * patients with any form of parkinsonism other than idiopathic pd. * patients for whom safinamide, rasagiline or any other anti-parkinson drug are contraindicated according to the current smpc. * patients known to be pregnant. * patients treated with safinamide or rasagiline who receive other concomitant mao-b inhibitors. * patients treated with other soc drugs who receive safinamide or rasagiline. * previous participation in a clinical trial with an investigational drug or medical device in the 3 months prior to the baseline visit.

Keywords: parkinson's pd safinamide rasagiline levodopa l-dopa fluctuating patients add-on therapy pdq updrs nrs quality of life observational
efficacy of preoperative education and mini-invasive surgery for total hip replacement

Conditions: Osteoarthritis of the Hip

Summary: we propose to evaluate a preoperative education of the patient and a new surgical technique (the mini-invasive thr) that could reduce the time to achieve functional independence. the primary objective of the trial is to assess the time to reach functional independence after total hip replacement depending on the treatment groups: preoperative education versus no preoperative education and mini-invasive procedure versus standard procedure. the study hypothesis is that education and mini-invasive procedure will reduce the time to reach functional independence. this is a prospective trial with a double randomization.

we propose to evaluate a preoperative education of the patient and a new surgical technique (the mini-invasive thr) that could reduce the time to achieve functional independence. preoperative education is compared to no education and the mini-invasive surgery is compared to the standard group. the education is based on explaining to the patient what will the postoperative rehabilitation be like. the mini-invasive thr is based on the minimisation of soft tissue trauma. it requires a specific instrumentation to allow dissection and implantation of the prosthesis. only few studies have evaluated such a technique. however, these studies were retrospective or non-randomised and results are contradictory. therefore, a randomised controlled clinical trial is necessary to evaluate the possible benefits and feasibility of this technique. the primary outcome is the time to reach functional independence. secondary outcomes evaluate the duration of hospital stay, the quality of implantation of the prosthesis, the postoperative morbidity, the functional benefits and the quality of life. methods: this monocentric randomised controlled clinical trial compares the preoperative education versus no preoperative education (first randomization) and the conventional thr to the mini-invasive thr (second randomization). one hundred and forty patients will be included in each group. expected results: preoperative education and the mini-invasive thr are prone to decrease time to functional independence, postoperative morbidity and duration of hospital stay.

Eligibility criteria:
inclusion criteria: * osteoarthritis of the hip * avascular necrosis of the hip * patient between 40 and 90 years old (included) exclusion criteria: * history of previous hip operation (bone) * patient \>90 or \< 40 * inflammatory arthritis * important proximal femur or acetabular deformity * complete functional independence not possible * bmi \> 30

Keywords: osteoarthritis, hip replacement, education, randomized controlled trial, mini-invasive surgery
evaluation of the functional impact of adenotonsilectomy

Conditions: Apnea, Obstructive; Tonsillitis; Tonsillar Hypertrophy; Respiratory Function Impaired; Infections; ENT Disorder

Summary: spirometric assessment of respiratory function before and after adenotonsillectomy surgery

spirometric assessment of respiratory function before and after adenotonsillectomy surgery study site at chuporto: department of otorhinolaryngology at chuporto, portugal. study design: institutional, observational, cohort, prospective. classification of studies according to the law of clinical investigation (dec. law no. 21/2014): clinical study without intervention. main objective of the study: to collect a database referring to pediatric patients enrolled for surgery in an outpatient setting, in order to compare vital, spirometric and clinical parameters at two different times: pre and post surgical intervention. secondary objectives of the study: based on validated indices, to assess the impact of surgical intervention on the child's respiratory and cardiovascular system. participants: patients undergoing surgery in the field of pediatric otorhinolaryngology at chuporto, a tertiary referral hospital in portugal.

Eligibility criteria:
inclusion criteria: * age between 4-14 years; * patients with surgical indication for any combination of: * tonsillectomy * adenoidectomy * turbinoplasty * myringotomy; * naive children (not submitted to previous ent surgery); * signature of informed consent by the parent entity. exclusion criteria: * age under 4 years and over 14 years; * surgery: myringotomy+tt placement exclusively; * associated co-morbidities: * asthma/other obstructive lung diseases * congenital facial or thoracic dysmorphism * neurological disease with cognitive impairment * cardiopulmonary disease * patients without surgical indication * other causes of nasal obstruction (severe septum deviation or polyps).

Keywords: adenotonsillectomy children spirometry obstructive sleep apnea adenotonsillar hypertrophy respiratory function